 Specificity low dose fadrozole hydrochloride CGS aromatase inhibitor CGS fadrozole hydrochloride potent cytochrome steroidogenesis inhibitor aromatase low doses biosynthetic steps concentrations Recent studies inhibition corticosterone methyloxidase-II deoxycorticosterone conversion agent concentrations blockade aromatase phase studies selective inhibition aromatase possible low doses CGS phase II study postmenopausal women metastatic breast cancer effects low dose CGS estrogen mineralocorticoid glucocorticoid secretion dose schedules dose levels prior dose escalation protocol study Plasma estrone estradiol sulfate urinary estrone estradiol mg CGS twice daily times dose schedule Isotopic kinetic studies decrease rate conversion androstenedione patients mg CGS regimens basal levels aldosterone cortisol period observation Clinical examination plasma electrolytes urinary sodium/potassium ratios biological evidence mineralo-corticoid deficiency ACTH-stimulated cortisol concentrations dose level values peak responses nmol/L basal difference nmol/L instances reflected inhibition basal ACTH-stimulated levels response CGS Androstenedione alpha-hydroxyprogesterone upward trend response drug treatment ACTH-stimulated aldosterone levels extent cortisol reflection corticosterone methyloxidase type II blockade results CGS doses mg daily blocks important inhibition cortisol aldosterone biosynthesis agent glucocorticoid mineralocorticoid supplementation